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Abstract
Aims/hypothesis We sought to establish the extent and basis
for adaptive changes in beta cell numbers in human
pregnancy.
Methods Pancreas was obtained at autopsy from women
who had died while pregnant (n=18), post-partum (n=6) or
were not pregnant at or shortly before death (controls; n=
20). Pancreases were evaluated for fractional pancreatic beta
cell area, islet size and islet fraction of beta cells, beta cell
replication (Ki67) and apoptosis (TUNEL), and indirect
markers of beta cell neogenesis (insulin-positive cells in
ducts and scattered beta cells in pancreas).
Results The pancreatic fractional beta cell area was increased
by ∼1.4-fold in human pregnancy, with no change in mean
beta cell size. In pregnancy there were more small islets rather
than an increase in islet size or beta cells per islet. No increase
in beta cell replication or change in beta cell apoptosis was
detected, but duct cells positive for insulin and scattered beta
cells were increased with pregnancy.
Conclusions/interpretation The adaptive increase in beta
cell numbers in human pregnancy is not as great as in most
reports in rodents. This increase in humans is achieved by
increased numbers of beta cells in apparently new small
islets, rather than duplication of beta cells in existing islets,
which is characteristic of pregnancy in rodents.
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Introduction
Glucose homeostasis is regulated by insulin, which is
secreted by pancreatic beta cells in a manner dependent on
glucose concentration. In type 1 and 2 diabetes, insulin
secretion is insufficient to maintain glycaemic control. In the
former, a near complete loss of beta cell mass occurs [1],
while in the latter, the deficit in beta cell mass is partial [2].
Beta cell mass has been reported to increase by two- to
fivefold in rodents in response to pregnancy [3–5]. This
observation has provoked interest in the signals that drive
this increase in beta cell mass in the hope that the same
signals might be harnessed to foster beta cell regeneration
in humans with diabetes [6]. However, there are limited
data on the adaptive changes in beta cell mass in humans
during pregnancy.
In human pregnancy, insulin sensitivity progressively
declines during the last 20 weeks of gestation [7]. In health,
this pregnancy-related insulin resistance is met with a
corresponding increase in insulin secretion [7–9] so that
plasma glucose values remain normal or even somewhat
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DOI 10.1007/s00125-010-1809-6decreased. The only available study of pancreas in humans
during pregnancy reported that the fraction of pancreas
occupied by beta cells increased 2.4-fold compared with
non-pregnant women [10]. However, only five cases were
studied and the morphological evaluation was limited.
In the present study, we sought to address the question
of: (1) whether there is an adaptive increase in beta cell
numbers and/or size during pregnancy in humans (and if so
to what extent?); and (2) whether any increase detected in
the number of beta cells in pregnancy is achieved
predominantly through replication of existing beta cells or
through formation of beta cells from sources independent of
beta cell replication (beta cell neogenesis).
Methods
Autopsy cases Human pancreatic tissue was obtained at
autopsy from 18 women who had died while pregnant, six
women who died post-partum, and 20 women who were not
pregnant at death (Tables 1, 2 and 3). Potential tissue
providers were identified by retrospective analysis of the
Mayo Clinic autopsy database. For inclusion in the study, a
full autopsy had to have been conducted within 24 h of death
and pancreatic tissue of adequate size and quality stored.
Exclusion criteria were if pancreatic tissue had undergone
autolysis or showed evidence of acute pancreatitis. None of
the deceased selected had had a history of diabetes or any
other diseases affecting the pancreas. Their characteristics
and diagnoses leading to death are presented in Tables 1, 2
and 3. Institutional Review Board approval was obtained
from the Mayo Clinic and University of California Los
Angeles (UCLA). Since death in pregnancy is fortunately
now rare, we accessed samples obtained at autopsy from the
late 1940s to early 2000s. The control tissue from women
who were not pregnant at death was obtained from pancreas
secured at autopsy over the same period. Death in the young
pregnant and non-pregnant women included in this study
typically followed a sudden catastrophic event (for example
road traffic accident). As such the medical record did not
provide a sufficiently robust family history of diabetes to
document with the pancreatic morphometric findings. Also,
fasting blood glucose values in health before the final
catastrophic illness were unavailable. Most women had not
Table 1 Clinical characteristics, pregnant women
Woman Gestation week
at death
Age at death
(years)
Pre-pregnancy
BMI (kg/m
2)
Beta cell
area (%)
Cause of death Fetal
viability
Pregnancy
history
1 22 22 22.2 2.03 Increased intracranial pressure
due to encephalitis
Not viable G1P0
2 10 31 19.9 2.81 Sudden death, unexplained Not viable G3P0
3 16 32 28 3.44 Acute respiratory paralysis polio Not viable G5P4
4 16 21 27.8 1.05 Overdose of barbiturates Not viable –
5 37 18 21.2 1.08 Diffuse cerebral oedema
(hypoxic encephalopathy)
Live G1P0
6 15 19 23.9 1.14 Trauma Stillborn G2P1
7 27 36 34.1 1.97 Myocardial failure secondary
to ARDS
Stillborn G2P1
8 18 25 22.5 0.60 Trauma Stillborn –
9 34 26 18.3 1.57 L temporal lobe abscess Live G4P3
10 36 42 28.0 3.20 Phaeochromocytoma,
hypertensive CVD
Stillborn G14P13
11 40 42 23.4 0.61 IPH, shock and coma Live G8
12 36 23 24 1.24 Thrombotic mitral stenosis Live G1P1
13 34 38 32.3 1.13 Amniotic fluid embolism Live twins G8 P6
14 15 31 25.6 1.01 Systemic lupus, cardiac arrest Not viable –
15 14 19 21.3 0.75 Ruptured AV malformation Not viable G1P0
16 10.5 40 26.8 2.19 Pulmonary hypertension Not viable –
17 40 38 30.7 2.56 Eclampsia Live G1P1
18 22 25 22.2 2.22 Acute liver failure (fulminant
HBsAg+ hepatitis)
Not viable G2P1
Mean 24.58 29.33 25.12 1.70
SEM 2.55 1.98 1.03 0.21
ARDS, acute respiratory distress syndrome; AV, arterial venous; CVD, cardiovascular disease; HBsAg, hepatitis B surface antigen; G, gravida;
IPH, intrapartum haemorrhage; P, para
2168 Diabetologia (2010) 53:2167–2176attended the Mayo Clinic previously, but were brought to the
medical centre for treatment of the final illness and autopsy.
Therefore our presumption that the women did not have
diabetes was based on the absence of a prior history of
diabetes or diabetes in their final illness, rather than on a
fasting evaluation in health. Since the controls were selected
to be of similar age, to have also died a sudden death and to
be matched for year of procurement of the pregnant
individuals, in health ambulatory fasting blood glucose
values were also unavailable in most of these cases.
The BMI of the pregnant women was calculated from
pre-pregnancy height and weight, and was comparable to
that of the control group (25.1±1.0 vs 22.2±1.1, pregnant
vs control, p=NS). The BMI was greater in the post-partum
than in the control group (30.2±4.3 vs 22.2±1.1, post-
partum vs control, p<0.05).
Table 2 Clinical characteristics, post-partum women
Woman Time of death
(days PP)
Age at death
(years)
Pre-pregnancy
BMI (kg/m
2)
Beta cell
area (%)
Cause of death Fetus
viability
Previous
pregnancies
15
a 30 29.1 1.06 Eclampsia Live G1P1
21 4
b 43 29.2 1.55 Cor pulmonale Live –
31 4
b 24 49.4 1.33 Pulmonary thromboembolism Live –
44
b 31 21.5 1.65 Staphylococcus septicaemia Live –
51
b 43 32.5 1.11 Endometritis, pulmonary haemorrhage Live G12P7
62 1
b 23 19.5 1.81 Toxaemia of pregnancy Live G3P3
Mean 32.33 30.20 1.42
SEM 3.61 4.34 0.12
aCaesarean section at week 31;
bfull term
G, gravida; P, para; PP, post-partum
Table 3 Clinical characteristics, control women
Woman Age at death BMI (kg/m
2) Beta cell area (%) Cause of death
1 27 17 1.19 Ruptured saccular aneurysm, respiratory arrest
2 29 18.7 2.05 Motor vehicle accident, blunt force chest injury
3 29 19.4 0.84 Strangulation by hanging
4 34 22.9 1.67 Seizure disorder, anoxic brain injury following cardiopulmonary arrest
5 19 22.6 1.19 Motor vehicle accident, closed head injury
6 35 23.7 1.00 Acute liver failure
7 31 19.7 1.46 Acute pneumonia
8 25 19.6 1.06 Congenital heart disease, VSD
9 18 17 1.48 Congenital heart disease, VSD
10 25 23.7 1.03 Acute liver failure (hepatitis)
11 26 20.9 0.77 Motor vehicle accident, head trauma
12 42 25.5 0.95 Asthma and bronchopneumonia
13 42 19.9 1.33 Thromboembolus right cerebral artery, cerebral infarct
14 32 19.7 1.94 Hypertensive pulmonary vascular disease
15 31 25.1 0.70 Smoke inhalation
16 22 22.9 1.27 Motor vehicle accident
17 18 17.7 0.93 Aeroplane crash, spinal trauma
18 31 22.9 0.51 Acute meningitis
19 37 27.5 0.99 Strangulation
20 33 38.4 1.35 Respiratory arrest, MI
Mean 29.30 22.24 1.19
SEM 1.57 1.07 0.10
MI, myocardial infarction; VSD, ventricular septal defect
Diabetologia (2010) 53:2167–2176 2169Pancreatic tissue processing At Mayo Clinic the tail of the
pancreas was resected at autopsy and a block of pancreas,
approximately 2.0×1.0×0.5 cm in size, along with a
sample of spleen, were fixed in formaldehyde prior to
being embedded in paraffin. Sections of these blocks were
obtained as previously described [2]. Sequential 5-μm
sections approximately 2×1 cm were stained as follows:
(1) for insulin (peroxidase staining) and haematoxylin for
light microscopy; (2) insulin, TUNEL and DAPI combined
(immunofluorescence); and (3) insulin, Ki67 and DAPI
combined (immunofluorescence).
For immunohistochemical staining, the following prima-
ry antibodies were used: guinea pig anti-insulin (1:200;
Dako Laboratories, Carpinteria, CA, USA) and mouse Ki67
(1:200, MIB-1; Dako). Secondary antibodies labelled with
Cy3 and fluorescein isothiocyanate were obtained from The
Jackson Laboratories (West Grove, PA, USA) and used at
dilutions of 1:100 to 1:200. For TUNEL staining, an in situ
cell death detection kit (KIT AP; Roche Diagnostics,
Indianapolis, IN, USA) was used.
Morphometric analysis To determine the pancreatic fractional
beta cell area, the entire pancreatic section was imaged at 40×
magnification (4× objective). The ratio of the beta cell area:
exocrine area was digitally quantified as previously described
[2] using a software package (Image Pro Plus version 4.5.1;
Media Cybernetics, Silver Springs, MD, USA). In brief,
digital images were made of pancreatic lobules (excluding the
interlobular connective tissue, large blood vessels and adipo-
cytes, and thus consisting to the greatest extent of pancreatic
acinar tissue and pancreatic islets). This and the other analyses
below were evaluated independently by two observers (A. E.
Butler and L. Cao-Minh) blinded as to the group from which
the slides to be evaluated came. UCLA-based investigators
remained blinded to the groups until the morphometric
analysis was completed, at which time the identity of the
groups was made available by R. A. Rizza from Mayo Clinic.
If the inter-observer measures of any variable in any sample
were more than 10%, A. E. Butler and L. Cao-Minh
independently re-evaluated the slide and rescored the variable.
To determine the frequency of beta cell replication, 100
islets per section were analysed from the section stained by
immunofluorescence for insulin, Ki67 and DAPI. Each islet
was viewed at 200× magnification (20× objective). The
total number of Ki67-positive beta cells was expressed as
Ki67-positive beta cells per 100 islets.
To determine the frequency of beta cell apoptosis, 100
islets per pancreas were analysed using the section stained
by immunofluorescence for insulin, TUNEL and DAPI
combined. The number of apoptotic beta cells was
expressed as TUNEL-positive beta cells per 100 islets.
To determine islet size and density, pancreatic sections
stained for insulin (peroxidase) and haematoxylin were
analysed. After assessment of the entire pancreatic section,
the largest islet in the section was identified, along with ten
other prominent islets. For each islet, the total islet size was
measured (Image Pro Plus), followed by measurement of
the insulin-positive area of each islet. The Wicksell
transform [11, 12] was applied to islet radii to address the
problem of estimating the real radii distribution from profile
radii by means of Bach’s eigenfunctions [13, 14].
Islet density was quantified by measuring a random area
of pancreas using Image Pro Plus and then counting the
number of islets contained within that pancreatic area, the
results being expressed as islets per mm
2. An islet was
defined as a cluster of four or more insulin-positive cells.
Similarly, Image Pro Plus was used to quantify the total
area of pancreas and then the number of individual
scattered insulin-positive cells contained within that area
of pancreas was counted; these results were expressed as
isolated insulin-positive cells per mm
2.
Insulin-positive duct cells were determined using the
insulin-stained sections of pancreas (peroxidase) counter-
stained with haematoxylin. In each autopsy sample, 50
pancreatic ducts were identified and the total number of
duct cells in those 50 ducts determined. The number of
insulin-positive cells in those ducts was also determined
and the result expressed as percentage of the total number
of duct cells.
Islet size distribution was determined using the insulin-
stained sections of pancreas (peroxidase) counterstained
with haematoxylin. The first 100 to 120 islets per individual
were grouped according to the number of insulin-positive
cells they contained per section, i.e. one to four cells, five to
nine cells, 10 to 19 cells, 20 to 49 cells and 50 or more beta
cells, and the data expressed as a percentage of islets.
To measure the whole-cell diameter of beta cells, insulin-
stained sections of pancreas (peroxidase) counterstained
with haematoxylin were used. Five islets per individual
selected at random were photographed at 400× magnifica-
tion on an inverted system microscope (Olympus I×70;
Olympus, Melville, NY, USA). These islets were then
examined to identify five representative beta cells in each.
Selection criteria included a circular shape (similar dimen-
sions in all directions) and the appearance to the observer
that the cell had been sectioned through its maximum
diameter. For determination of the mean cell diameter, five
distances between two adjacent beta cell nuclei (including
one of the nuclei) were measured in each of the five islets.
The mean individual beta cell area was calculated from the
measured mean cell diameter in each autopsy case,
assuming a spherical shape of beta cells.
Statistical analysis Data are presented as means ± SE.
Statistical calculations were carried out using GraphPad
Prism 4 (GraphPad Software, San Diego, CA, USA). We
2170 Diabetologia (2010) 53:2167–2176sought to address two specific questions a priori in the
present studies: first, is there an adaptive increase in beta
cell numbers and/or size during pregnancy in humans, and
if so to what extent? Second, is any increase in beta cell
numbers detected achieved predominantly through replica-
tion of existing beta cells or through formation of beta cells
from sources independent of beta cell replication (beta cell
neogenesis)? To address these questions we used the non-
paired Student’s t test with p<0.05 taken to represent a
significant difference. The six women who had died post-
partum were identified unexpectedly and included because
of the rarity of available data. As a second and separate
analysis we sought to establish whether there was a retained
adaptive increase in fractional pancreatic beta cell area in the
post-partum state. Since this was a separate analysis the t test
was also employed for this question, recognising the
limitations of using any statistical analysis with just six cases.
Results
Fractional beta cell area The pancreatic fractional area
positive for insulin was increased 1.4-fold in the pregnant
compared with control women (1.7±0.2% vs 1.2±0.1
pregnant vs control, p<0.05) (Fig. 1). The pancreatic
fractional beta cell area in the post-partum women was
higher than in the controls (1.4±0.1%), but not significantly
so. This comparison should also be considered in the
context that BMI was higher in the post-partum than in the
non-pregnant women.
Islet size and density The measured mean islet radius was
decreased in pregnancy (45.0±24.6 vs 52.6±28.1 μm,
pregnancy vs controls) and remained decreased in the
post-partum women (34.4±20.0 μm). The frequency
distribution of the profile radii and the probability distribu-
tions of islet radii after Wicksell transform are provided in
Electronic supplementary material (ESM) Fig. 1. The mean
islet cross-sectional area was decreased in pregnancy (8.9±
0.8 vs 11.1±0.9 μm
2×10
3, p<0.05, pregnant vs control)
(Fig. 2a). There was also a decrease in the mean insulin-
positive area per islet in pregnancy (7.0±0.5 vs 8.4±
0.5 μm
2×10
3, p<0.05 pregnant vs control) (Fig. 2b). The
mean islet cross-sectional area (7.8±0.6 vs 11.1±0.9 μm
2×
10
3, p<0.05, post-partum vs control) and insulin area per
islet (6.2±0.6 vs 8.4±0.5 μm
2×10
3, p<0.05 post-partum vs
control) remained less than that of controls in the post-
partum women (Fig. 2a,b).
Since the overall fractional area of the pancreas that was
positive for insulin was increased, while the mean insulin
area per islet was decreased in pregnancy, we anticipated
that in pregnancy islet density would be increased. This
was confirmed (7.7±0.8 vs 5.1±0.3 islets per mm
2, p<0.01,
pregnant vs control) (Fig. 2c). Islet density remained
increased in the post-partum women (7.4±1.4 vs 5.1±0.3
islets per mm
2, p<0.05, post-partum vs control) (Fig. 2c).
Comparison of pancreas sections from pregnant with those
from control women revealed that this increased islet
density was composed primarily of islets of comparable or
smaller size than those in non-pregnant women (Fig. 3).
Since the finding that, on average, islets were smaller in
human pregnancy was the opposite of that observed in
Fig. 1 The mean fractional pancreatic beta cell area in non-pregnant
controls, and in women who were pregnant or in the post-partum state.
During pregnancy the mean fractional beta cell area was 1.4-fold
increased (*p<0.05) compared with the controls
Fig. 2 Mean islet size (a), mean area per islet positive for insulin (b)
and mean islet density (c) in non-pregnant controls, and in women
who were pregnant or in the post-partum state; values determined by
evaluating ten prominent islets per woman. During pregnancy and
post-partum the mean islet size and the mean insulin area per islet
were decreased (*p<0.05) compared with non-pregnant controls. Islet
density (c) was increased (**p<0.01 pregnant; *p<0.05 post-partum)
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increased in size during human pregnancy, but were not
identifiable by measurement of mean islet size? To address
this, we measured the total islet area and islet fractional area
in the largest islet per section per tissue source. The cross-
sectional area of the largest islet identified per section was
not increased in pregnancy (55.6±6.8 vs 54.8±5.5 μm
2×
10
3; pregnant vs control, p=NS). Likewise there was no
increase in the mean insulin-positive cross-sectional area in
the largest islet per section in pregnancy compared with
controls (42.0±4.4 vs 38.8±3.6 μm
2×10
3, p=NS). In the
post-partum women, the total islet cross-sectional area of
the largest islet was comparable to controls (60.8±
11.1 μm
2×10
3, p=NS vs controls), as was the mean
insulin-positive cross-sectional area of the largest islet
(40.3±5.3 μm
2×10
3, p=NS vs controls).
To evaluate more directly the impression that there were
more, but smaller islets in pregnancy, we examined the
abundance of islets by number of beta cells per islet as seen
on cross section. The resulting islet size frequency distribu-
tion reveals a shift towards smaller islets in pregnant and
post-partum women compared with controls (Fig. 4, ESM
Fig. 1), although the majority of beta cells were present in
intermediate-sized islets.
Insulin-positive duct cells and isolated beta cells The
percentage of pancreatic duct cells immunoreactive for
insulin was increased in pancreases from pregnant and post-
partum women compared with non-pregnant controls
(pregnant vs post-partum vs control: 1.2±0.2 vs 1.0±0.2
vs 0.4±0.1%, p<0.005 pregnant vs control, p<0.01 post-
partum vs control) (Fig. 5a). Likewise, the frequency of
isolated insulin-positive cells in the exocrine pancreas was
comparably increased in pregnant and post-partum women
compared with control (pregnant vs post-partum vs control
4.0±0.5 vs 4.5±1.0 vs 1.5±0.1 individual insulin-positive
cells per mm
2, p<0.001 control vs pregnant and post-
partum [Fig. 5b]).
Fig. 4 The frequency distribution of beta cells per islet on section in
non-pregnant controls (white bars), and in women who were pregnant
(black bars) or in the post-partum state (grey bars). There was a
marked shift towards small islets in pregnancy and in the post-partum
state compared with the non-pregnant state. This shift is the opposite
to that observed in pregnant rodents, in which more abundant large
islets have been detected
Control ×4
Pregnancy ×4 
22 weeks, gestation
Control ×20
Pregnancy ×20 
22 weeks, gestation
ab
cd
Fig. 3 Sections of pancreas from control women (a, c) and pregnant
women at 20 weeks (b) and 22 weeks (d) of gestation. Images were
generated at low power (4×) (a, b) and at higher power (20×) (c, d),
with samples stained for insulin (brown) and counterstained by
haematoxylin. While a range of islet sizes is apparent on cross-
section in both cases, the abundance of small islets is increased in the
pregnant women
Fig. 5 The mean percentage of pancreatic duct cells positive for
insulin (a) and the abundance of single scattered beta cells (b)i n
pregnant controls, and in women who were pregnant or in the post-
partum state. These indices, which have been used previously as
indirect measures of beta cell neogenesis, were both increased with
pregnancy, remaining so post-partum. ***p<0.001 vs control;
†p<
0.005 vs control
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control, replication detected by Ki67 immunostaining and
apoptosis detected by TUNEL were comparably abundant
in sections of spleen from control, pregnant and post-
partum women (ESM Fig. 2). In contrast, beta cell
replication and beta cell apoptosis were rarely detected.
The frequency of beta cell replication was not increased in
pregnancy (0.89±0.42 vs 0.95±0.59 Ki67-positive beta
cells per 100 islets, p=NS pregnant vs control) (Fig. 6a).
There was also no change in the frequency of beta cell
apoptosis in pregnancy (0.06±0.06 vs 0.05±0.06 TUNEL-
positive beta cells per 100 islets, p=NS pregnant vs control)
(Fig. 6b). Because of the low frequency of replication and
apoptosis, and the relatively small number of women in the
post-partum group, the data were insufficient to be
meaningful.
Beta cell hyperplasia vs hypertrophy To establish if the
∼50% increase in pancreatic insulin-positive fractional beta
cell area in pregnancy was due to increased beta cell size or
number, we compared mean beta cell size by evaluating the
mean cross-sectional area per beta cell in each group. Beta
cells were not enlarged in pregnancy as judged by mean
cross-sectional area of individual beta cells (71.2±4.6 vs
68.2±3.3 μm
2, p=NS pregnant vs control). Interestingly,
however, beta cells were on average larger in the post-
partum period than during pregnancy or in the non-
pregnant women (80.4±6.7 vs 68.2±3.3 μm
2, p<0.05
post-partum vs control).
Discussion
The present studies are in agreement with the one previous
report on human pancreas obtained at autopsy in pregnant
humans, which indicated an adaptive increase in beta cell
numbers [10].
Not surprisingly, given the limitations of autopsy studies,
the present report and that of Van Assche and colleagues
differed somewhat in the extent to which the numbers of
beta cells increased in response to pregnancy. While we
report an approximately 1.4-fold increase in fractional beta
cell area in pregnant vs non-pregnant women, Van Assche
and colleagues reported an approximately 2.4-fold increase
in beta cell fractional area. They also reported an expansion
in islet size and beta cells per islets in pregnancy, which we
did not observe. Several differences between the studies
may account for this. Van Assche and colleagues measured
the fractional endocrine and beta cell area with Ivic’s
Victoria blue acid fuchsin staining, whereas we used insulin
immunohistochemistry to define beta cells. While we were
able to include 18 pregnant, six post-partum and 20 non-
pregnant control women, Van Assche and colleagues
evaluated five pregnant and five non-pregnant women. It
is also possible that underlying diseases leading to death in
the individuals included in both studies might have
influenced the fractional beta cell area. In the present study,
we were also able to examine beta cell replication and
apoptosis. In contrast to rodent studies [3–5], we did not
find an increase in beta cell replication during pregnancy in
humans.
The absence of a documented increase in beta cell
replication during pregnancy in humans cannot simply be
attributable to use of autopsy tissue, since the spleen from
women studied was examined as positive control and
abundant specific nuclear Ki67 staining was readily
detected in those sections. By the same approach, more-
over, we were readily able to detect beta cell replication in
infants [15]. In rodents, the increase in beta cell replication
during pregnancy occurs during a relatively short period at
mid gestation [5]. It is plausible that the same occurs in
human pregnancy, but that we had no women of the
appropriate gestation period to catch that window. Howev-
er, if the increase in beta cell numbers in human pregnancy
is predominantly achieved by replication of existing beta
cells, then the increase in beta cell mass could be expected
to be accompanied by an increase in mean islet size and
mean number of beta cells per islet, as apparent in rodents
during pregnancy [3–5]. In contrast to rodents, we found no
Fig. 6 The mean frequency of beta cell replication by Ki67 (a) and
apoptosis by TUNEL (b) in non-pregnant controls and in pregnant
women. As previously reported in humans, both indices are infrequent
implying relatively slow beta cell turnover. No detectable change in
either was observed in pregnancy. Given the low frequency of these
measures and the limited pancreatic tissue available per woman, data
were insufficient to allow reliable documentation of frequency of these
variables in the six post-partum women
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islet; indeed, we found the contrary.
One possible explanation for the smaller increase in beta
cell numbers in humans compared with rodents, as well as
for the absence of increased beta cell replication in response
to pregnancy comes from recent studies showing that beta
cell epigenetic changes during ageing markedly decrease
the capacity for beta cell replication [16–19]. To date, most
rodent studies have been performed at an age that precedes
these epigenetic changes. It is as yet unknown to what
extent beta cell mass adaptively increases in rodents in
response to pregnancy after the epigenetic changes that
limit beta cell replication have occurred.
Since the increase in beta cell numbers observed in
human pregnancy resulted from an increase in density of
islets, it is plausible that the adaptive increase in beta cells
in humans is achieved by formation of new islets or islet
neogenesis. The notion of islet and/or beta cell neogenesis
after birth is controversial. Lineage studies in rodents have
been interpreted as showing that replication of existing beta
cells is the only potential source of new beta cells [20]. A
variety of approaches independent of lineage tracing have
been used to support the concept of beta cell formation
occurringindependentlyofbetacellduplication[2, 3, 21–25].
We used two of these in the present manuscript, namely
determination of (1) the presence and extent of beta cells in
exocrine ducts and (2) the abundance of single beta cells
scattered in exocrine tissue; in both we detected increases
during pregnancy. Recent lineage tracing approaches have
also been used to support the concept of beta cell neogenesis
in rodents, but these obviously cannot be applied in humans
[26, 27].
Gestational diabetes is due to an insufficient adaptive
increase in insulin secretion in response to the insulin
resistance that occurs in pregnancy [28]. In health, the
increased requirement for insulin secretion in pregnancy is
approximately twofold [9], exceeding the increment in beta
cell numbers observed here. These data imply that in health
the adaptive increase in insulin secretion in pregnant
humans is achieved in part by an increased work load
(insulin synthesis and secretory burden) per beta cell. Since
beta cell failure in type 2 diabetes is best predicted by beta
cell work load [29] and is characterised by endoplasmic
stress [30, 31], it is not surprising that gestational diabetes
occurs in those genetically predisposed to type 2 diabetes.
Several studies have reported increased detectable C-
peptide during pregnancy in patients with type 1 diabetes
[32, 33]. This might be due to new beta cell formation in
the setting of relative immunosuppression during pregnancy
[34] or, possibly, to enhanced beta cell function in residual
beta cells with intensified glycaemic control.
In the present studies, the fractional beta cell area
increase in pregnancy was established early (Table 1), even
though the most prominent levels of insulin resistance in
pregnancy do not develop until the third trimester [7, 8].
These findings are intriguing since it has previously been
shown that the increment in first- and second-phase insulin
release in response to glucose during pregnancy is present
early in pregnancy (first trimester), while the insulin
resistance that develops in pregnancy occurs later (third
trimester) [7]. Taking these findings together, this implies
that the signal that provokes the early increase in glucose-
induced insulin secretion in human pregnancy may do so at
least in part through fostering an increase in beta cell
formation. It also implies that the factor(s) driving the
expansion of beta cell numbers in human pregnancy are
independent of the major decline in insulin sensitivity that
occurs in the third trimester. Interestingly, as evaluated in
patients with type 1 diabetes, insulin requirements increase
early in pregnancy (up to week 9) [35]—an increase that,
though not as marked as that occurring from week 18 to
term, coincides with the increment in beta cell numbers in
humans during pregnancy as observed in the present study.
Since mechanisms that signal an expansion of beta cell
mass in pregnancy are of interest as a potential means to
promote beta cell regeneration in diabetes, it would appear
that in humans such signals would best be identified in the
first trimester.
Beta cell mass can theoretically increase because of an
increase in new cell formation or a decrease in cell death
(prolonged beta cell survival). In healthy humans, the
frequency of beta cell apoptosis is very low [3] presumably
reflecting a relatively long beta cell life span [36]. Thus
there is little scope for adaptive changes in beta cell
apoptosis to increase beta cell mass during pregnancy. We
did not document any decrease in the low frequency of beta
cell apoptosis in human pregnancy.
However, we did note a decrease in fractional beta cell
area in the few post-partum women studied compared with
pregnant women, although this decrease was not complete-
ly to the baseline present in controls. Interestingly, the post-
partum women included in the present study were more
obese than either the pregnant or control women. Since
obesity is associated with an increase in beta cell mass in
humans [37], the failure of pancreatic fractional beta cell
area to return to pre-pregnant levels in our post-partum
women may have been due to the insulin resistance/
inflammation associated with the obesity. The post-partum
women retained the pattern of having more (but small)
islets than did non-pregnant women, implying (1) that these
putative new islets are not immediately and selectively lost
after birth; or (2) that they formed partly in response to
obesity. Given the smaller size of the post-partum group,
and the low frequency of beta cell replication and apoptosis
in human pancreas, we had insufficient numbers to
establish a meaningful record of these variables in this
2174 Diabetologia (2010) 53:2167–2176group. While we did not observe any difference in mean
beta cell size in human pregnancy, beta cells, interestingly,
were on average larger in the post-partum period, perhaps
reflecting the accumulation of granules with a decreased
secretory burden per beta cell, since beta cell numbers did
not undergo as rapid a decrease in humans as previously
reported in rodents after pregnancy [4].
In summary, we report that there is an adaptive increase
in beta cell numbers in human pregnancy, although it is
more limited in extent than that in rodents. Also, the pattern
of increase differs from that in rodents, with increased
numbers of islets in human pregnancy in contrast to an
increase in islet size due to the increased beta cell
replication observed in rodent pregnancy. Indirect evidence
in human pregnancy supports the notion that at least some
beta cell formation arises from sources other than beta cell
replication (beta cell and/or islet neogenesis). While our
studies support the concept that study of enhanced beta cell
numbers in pregnancy may help develop strategies to
promote beta cell regeneration in diabetes, they suggest
that caution should be exercised when assuming that the
mechanisms inducing increased beta cell replication during
pregnancy in rodents would also effectively induce an
expansion of beta cell mass in humans.
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